Ondansetron Hydrochloride Injection

This product is a potent, highly selective 5-HT3 receptor antagonist with a strong antiemetic effect. Chemotherapy drugs and radiotherapy can cause the small intestine to release 5-HT, which activates the afferent branch of the vagus nerve through the 5-HT3 receptor and triggers the vomiting reflex. This product can block the triggering of this reflex. The excitement of the afferent branch of the vagus nerve can also cause the release of 5-HT in the Postrema area at the bottom of the fourth ventricle, thereby enhancing it through the central mechanism. This product is effective for nausea and vomiting caused by chemotherapy and radiotherapy, so this product exerts an antiemetic effect by antagonizing the 5-HT receptors of neurons located in the peripheral and central nervous systems. The mechanism of action of postoperative nausea and vomiting is unclear, but it may be induced by the common pathway of nausea and vomiting caused by cytotoxic drugs. This product can also inhibit nausea induced by opioids, and its mechanism of action is still unclear. Due to the high selectivity of this product, it does not have the side effects of other antiemetics, such as extrapyramidal reactions and excessive sedation.

The main ingredient of this product is ondansetron hydrochloride.

Antiemetic. Used for: 1. Nausea and vomiting caused by cytotoxic chemotherapy and radiotherapy; 2. Prevention and treatment of postoperative nausea and vomiting.

This product is administered by intravenous or intramuscular injection, and the dosage can be flexibly controlled; 1. Chemotherapy-induced vomiting: The dosage and route of administration should be determined according to the severity of nausea and vomiting caused by chemotherapy and radiotherapy; (1) Adults: ① For vomiting caused by highly emetic chemotherapy drugs: 8 mg of ondansetron injection is injected intravenously 15 minutes before chemotherapy, 4 hours and 8 hours after chemotherapy, and 8 mg of ondansetron tablets are taken orally every 8 to 12 hours after chemotherapy is stopped, for 5 consecutive days; ② For vomiting caused by chemotherapy drugs that are not so emetic: 8 mg of ondansetron injection is injected intravenously 15 minutes before chemotherapy, and 8 mg of ondansetron tablets are taken orally every 8 to 12 hours thereafter, for 5 consecutive days. ③ For vomiting caused by radiotherapy: The first dose should be taken orally as a tablet 1 to 2 hours before radiotherapy, and then 8 mg is taken orally every 8 hours thereafter. The course of treatment depends on the course of radiotherapy; ④ For the prevention of nausea and vomiting after surgery: 4 mg is infused intravenously at the same time as anesthesia. ⑤ For high-dose cisplatin, 20 mg of dexamethasone sodium phosphate can be added intravenously before chemotherapy to enhance the efficacy of Zofran on vomiting caused by highly emetic chemotherapy; (2) Children: 5 mg/m2 (body surface area) is injected intravenously before chemotherapy, and then taken orally 12 hours later; oral administration should be continued after chemotherapy for 5 consecutive days; (3) Elderly patients: The efficacy and tolerance of patients over 65 years old are the same as those of ordinary adult patients, and there is no need to adjust the dose, frequency of medication or route of administration. 2 Postoperative nausea and vomiting: (1) Adults: To prevent nausea and vomiting after surgery, 4 mg of this product should be injected intramuscularly or slowly intravenously at the same time as induction of anesthesia. For postoperative nausea and vomiting that has occurred, a dose of 4 mg can be injected intramuscularly or slowly intravenously; (2) Children: To prevent postoperative nausea and vomiting in children undergoing general anesthesia, this product should be slowly injected intravenously at a dose of 0.1 mg/kg or a maximum dose of 4 mg before, during or after induction of anesthesia. For children who have experienced postoperative nausea and vomiting, this product can be slowly injected intravenously at a dose of 0.1 mg/kg or a maximum of 4 mg. (3) Elderly patients: the dosage, route and time interval should refer to those for adults.

There may be headache, abdominal discomfort, constipation, dry mouth, rash, occasional bronchial asthma or allergic reactions, and transient asymptomatic increase in transaminase. The above reactions are mild and do not require special treatment. There are rare reports of movement disorders, epileptic seizures, chest pain, arrhythmia, hypotension, and bradycardia.

1. Those who are allergic to this product are prohibited from using it. Those with gastrointestinal obstruction are not allowed to use it; 2. Pregnant women and lactating women should use it with caution.

Precautions during pregnancy and lactation: Use with caution in pregnant and lactating women.

1. There is no evidence that this product will induce or inhibit the metabolism of other drugs taken at the same time. Special studies have shown that this product has no interaction with alcohol, temazepam, furosemide, tramadol and propofol; 2. Patients with poor metabolism of separteine and isoquine have no effect on the elimination half-life of this product. After repeated administration to such patients, the exposure level of the drug is no different from that of normal humans, so the dosage and frequency of medication do not need to be changed; 3. Combination with dexamethasone can enhance the antiemetic effect; 4. It is compatible with the following intravenous injections: 0.9% W/V sodium chloride intravenous infusion (British Pharmacopoeia); 5% W/V glucose intravenous infusion (British Pharmacopoeia); 10% W/V mannose intravenous infusion (British Pharmacopoeia); Green's intravenous infusion solution; 0.3% W/V potassium chloride and 0.9% W/V glucose intravenous infusion (USP); 0.3% W/V potassium chloride and 5% W/V glucose infusion (British Pharmacopoeia). This product can only be mixed with the recommended intravenous infusion solution, and the solution for intravenous infusion should be prepared immediately. However, under fluorescent irradiation at room temperature (below 25°C) or in a refrigerator, this product can remain stable for seven days after being mixed with the above intravenous infusion solution; 5 This product can be intravenously infused with an infusion bag or injection pump, 1 mg per hour. If the concentration of this product is 16-160mu;g/ml (i.e. 8mg/500ml and 8mg/50ml respectively), the following drugs can be administered through the Y-shaped tube of the Zofran drug delivery device: cisplatin, 5Fu, carboplatin, etoposide, cyclophosphamide, doxorubicin and ceftriaxone, etc.

Store below 30℃ away from light.

4ml:8mg (based on ondansetron)

Chengdu Pingyuan Pharmaceutical Co., Ltd.

• Founded in:

  2003-09-25

• Address:

  Middle section of Pingyuan Road, Qionglai City

• Tax NO.:

  91510183752833128X

• Registered Funds:

  30 million yuan

• Website:

  Log in to view

• Email:

  Log in to view